Health Care·Biotechnology·$5.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.67 | N/A | -699.04% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.67 | N/A | -699.04% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed a cautious approach due to the lack of revenue updates. They emphasized the importance of their clinical programs.
Management did not provide specific revenue figures or guidance for the upcoming quarters.
The focus remains on ongoing clinical trials and product development.
PTC Therapeutics reported a significant loss per share, which was not unexpected as no revenue figures were disclosed. Despite the disappointing EPS, the stock rose by 1.41%, possibly due to investor optimism about ongoing clinical trials and product development. The lack of guidance may leave investors cautious about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PALO ALTO NETWORKS I
Feb 17, 2026